All News & Press

4.13.2021

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Read more >

3.30.2021

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

Read more >

3.22.2021

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Read more >

3.17.2021

Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Read more >

3.16.2021

Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference

Read more >

3.15.2021

Cybin to Present at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference

Read more >

3.10.2021

Cybin to Present at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Read more >

3.9.2021

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Read more >

3.8.2021

Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021

Read more >

3.3.2021

Cybin Inc. Announces Uplisting to OTCQB Venture Market

Read more >

2.16.2021

Cybin Inc. Releases Financial Highlights and Provides Business Update

Read more >

2.4.2021

Cybin Announces Upsize to Previously Announced bought Deal Offering

Read more >

2.3.2021

Cybin Announces Closing of Upsized Bought Deal Offering

Read more >

1.27.2021

Cybin included in First Psychedelic Exchange Traded Fund

Read more >

1.18.2021

Cybin Announces CDN $20 Million bought Deal Offering

Read more >

1.11.2021

Cybin partners with Kernel to Leverage its Neuroimaging Technology

Read more >

1.5.2021

Cybin Provides Update On Patent Filings & Development Of Therapeutics Program

Read more >

12.29.2020

Cybin Announces First Quarter Financial Results of Clarmin Explorations Inc.

Read more >

12.14.2020

Cybin closes Aquisition of Adelia Therapeutics and Grows IP Portfolio to 7 Patent Filings

Read more >

12.7.2020

Cybin Signs Definitive Agreement To Acquire Adelia Therapeutics As Part Of Its Commitment To Strategic Growth

Read more >

11.10.2020

Cybin Goes Public On NEO Exchange

Read more >

11.5.2020

Cybin Completes Reverse Take-Over Transaction

Read more >

9.1.2020

Cybin Corp Announces Doug Drysdale as Chief Executive Officer

Read more >

8.7.2020

Cybin Applauds TheraPsil’s Advocacy to Bring Psilocybin Therapy to Palliative Care of Canadian Patients

Read more >

7.21.2020

Cybin Corp. Announces Proposed Management Team and Board of Directors of the Resulting Issuer

Read more >

7.7.2020

Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

Read more >

6.29.2020

Cybin Corp. Announces Reverse Take-Over Transaction and the Engagement of Stifel GMP and Eight ...

Read more >

2.12.2020

Cybin Corp Announces Partnership with the Toronto Centre for Psychedelic Science

Read more >
2.1.2021

More Psychedelic Companies are going Public

Read more >
1.25.2021

Horizons CEO Steve Hawkins on Launching the First Psychedelic Stock ETF (PSYK)

Read more >
1.17.2021

Cybin, Bryan Johnson and the Greatest Impact on the Future

Read more >
1.12.2021

The Emerging Revival of Psychedelics in Neuroscience

Read more >
1.10.2021

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

Read more >
1.7.2021

5 Groovy Psychedelic Stocks to Buy

Read more >
12.27.2020

2020 was the Year of Psychedelics, Here's why

Read more >
10.24.2020

Psyched: Cybin Raises CA$45M, Numinus Harvests Legal Mushrooms, Toadstool Enters Psychedelic Space

Read more >
close

Our site uses cookies. Learn more about our privacy policy.

I accept the use of cookies